Page last updated: 2024-11-05

ticlopidine and Heart Septal Defects, Ventricular

ticlopidine has been researched along with Heart Septal Defects, Ventricular in 3 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Heart Septal Defects, Ventricular: Developmental abnormalities in any portion of the VENTRICULAR SEPTUM resulting in abnormal communications between the two lower chambers of the heart. Classification of ventricular septal defects is based on location of the communication, such as perimembranous, inlet, outlet (infundibular), central muscular, marginal muscular, or apical muscular defect.

Research Excerpts

ExcerptRelevanceReference
"A perimembranous ventricular septal defect (7 mm) and an ostium secundum atrial septal defect (8."1.37[Simultaneous transcatheter treatment of perimembranous ventricular septal defect and secundum atrial septal defect in an adult: first application in Turkey]. ( Arı, H; Arı, S; Bozat, T; Koca, V, 2011)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arı, H1
Arı, S1
Koca, V1
Bozat, T1
Avlonitis, VS1
Planas, S1
Hayes, AM1
Parry, A1
Saitoh, H1
Takayama, T1
Matsumoto, H1
Furuse, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age[NCT00833703]Phase 349 participants (Actual)Interventional2009-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants According to Bleeding Type/Etiology

For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. (NCT00833703)
Timeframe: Up to a maximum of 6 months

,
Interventionparticipants (Number)
SpontaneousPuncture (vascular access site)
Clopidogrel 0.2 mg/kg/Day11
Placebo00

Number of Participants With Bleeding Events

"All bleeding events experienced during the study period were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted." (NCT00833703)
Timeframe: Up to a maximum of 6 months

,
Interventionparticipants (Number)
Any bleeding event- Serious- Serious with an outcome of death- Leading to permanent treatment discontinuation
Clopidogrel 0.2 mg/kg/Day2000
Placebo0000

Number of Participants With Shunt Thrombosis Requiring Intervention or Deaths

"Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded.~Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first)." (NCT00833703)
Timeframe: Up to a maximum of 6 months

,
Interventionparticipants (Number)
shunt thrombosis requiring interventiondeath
Clopidogrel 0.2 mg/kg/Day00
Placebo01

Reviews

1 review available for ticlopidine and Heart Septal Defects, Ventricular

ArticleYear
[Pregnancy and delivery of a patient with a prosthetic aortic valve treated with antiplatelet drugs: a case report].
    Kyobu geka. The Japanese journal of thoracic surgery, 1987, Volume: 40, Issue:10

    Topics: Adult; Aortic Valve; Blood Platelets; Dipyridamole; Female; Heart Septal Defects, Ventricular; Heart

1987

Other Studies

2 other studies available for ticlopidine and Heart Septal Defects, Ventricular

ArticleYear
[Simultaneous transcatheter treatment of perimembranous ventricular septal defect and secundum atrial septal defect in an adult: first application in Turkey].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2011, Volume: 39, Issue:2

    Topics: Anesthetics, Intravenous; Clopidogrel; Echocardiography, Transesophageal; Female; Fluoroscopy; Heart

2011
Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:2

    Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Clopidogrel; Fatal Outcome; Graft Occlusion, Vas

2012